TY - JOUR
T1 - Comparison of physical activity sensors and heart rate monitoring for real-Time activity detection in type 1 diabetes and control subjects
AU - Manohar, Chinmay
AU - O'Keeffe, Derek T.
AU - Hinshaw, Ling
AU - Lingineni, Ravi
AU - McCrady-Spitzer, Shelly K.
AU - Levine, James A.
AU - Carter, Rickey E.
AU - Basu, Ananda
AU - Kudva, Yogish C.
PY - 2013/9/1
Y1 - 2013/9/1
N2 - Background: Currently, patients with type 1 diabetes decide on the amount of insulin to administer based on several factors, including current plasma glucose value, expected meal input, and physical activity (PA). One future therapeutic modality for patients with type 1 diabetes is the artificial endocrine pancreas (AEP). Incorporation of PA could enhance the efficacy of AEP significantly. We compared the main technologies used for PA quantitation. Subjects and Methods: Data were collected during inpatient studies involving healthy control subjects and type 1 diabetes. We report PA quantified from accelerometers (acceleration units [AU]) and heart rate (HR) monitors during a standardized activity protocol performed after a dinner meal at 7 p.m. from nine control subjects (four were males, 37.4±12.7 years old, body mass index of 24.8±3.8 kg/m2, and fasting plasma glucose of 4.71±0.63 mmol/L) and eight with type 1 diabetes (six were males, 45.2±13.4 years old, body mass index of 25.1±2.9 kg/m2, and fasting plasma glucose of 8.44±2.31 mmol/L). Results: The patient-To-patient variability was considerably less when examining AU compared with HR monitors. Furthermore, the exercise bouts and rest periods were more evident from the data streams when AUs were used to quantify activity. Unlike the AU, the HR measurements provided little insight for active and rest stages, and HR data required patient-specific standardizations to discern any meaningful pattern in the data. Conclusions: Our results indicated that AU provides a reliable signal in response to PA, including low-intensity activity. Correlation of this signal with continuous glucose monitoring data would be the next step before exploring inclusion as input for AEP control.
AB - Background: Currently, patients with type 1 diabetes decide on the amount of insulin to administer based on several factors, including current plasma glucose value, expected meal input, and physical activity (PA). One future therapeutic modality for patients with type 1 diabetes is the artificial endocrine pancreas (AEP). Incorporation of PA could enhance the efficacy of AEP significantly. We compared the main technologies used for PA quantitation. Subjects and Methods: Data were collected during inpatient studies involving healthy control subjects and type 1 diabetes. We report PA quantified from accelerometers (acceleration units [AU]) and heart rate (HR) monitors during a standardized activity protocol performed after a dinner meal at 7 p.m. from nine control subjects (four were males, 37.4±12.7 years old, body mass index of 24.8±3.8 kg/m2, and fasting plasma glucose of 4.71±0.63 mmol/L) and eight with type 1 diabetes (six were males, 45.2±13.4 years old, body mass index of 25.1±2.9 kg/m2, and fasting plasma glucose of 8.44±2.31 mmol/L). Results: The patient-To-patient variability was considerably less when examining AU compared with HR monitors. Furthermore, the exercise bouts and rest periods were more evident from the data streams when AUs were used to quantify activity. Unlike the AU, the HR measurements provided little insight for active and rest stages, and HR data required patient-specific standardizations to discern any meaningful pattern in the data. Conclusions: Our results indicated that AU provides a reliable signal in response to PA, including low-intensity activity. Correlation of this signal with continuous glucose monitoring data would be the next step before exploring inclusion as input for AEP control.
UR - http://www.scopus.com/inward/record.url?scp=84883398960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883398960&partnerID=8YFLogxK
U2 - 10.1089/dia.2013.0044
DO - 10.1089/dia.2013.0044
M3 - Article
C2 - 23937615
AN - SCOPUS:84883398960
SN - 1520-9156
VL - 15
SP - 751
EP - 757
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 9
ER -